Article Details

FDA Activity Recap: June 2024 Features Expanded Indication Approval, a CRL, RMAT ...

Retrieved on: 2024-07-06 17:15:14

Tags for this article:

Click the tags to see associated articles and topics

FDA Activity Recap: June 2024 Features Expanded Indication Approval, a CRL, RMAT .... View article details on hiswai:

Summary

The article discusses recent FDA actions in the biotech field, including the expanded approval of Sarepta Therapeutics' DMD gene therapy (Elevidys) and other approvals, responses, and designations impacting gene and cell therapies. These updates align with the key concept 'biotech' and relevant tags.

Article found on: www.cgtlive.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up